Aclaris Therapeutics Reports Positive Phase 1A Results for ATI-052, Plans Phase 2B in Asthma
Summary
Aclaris Therapeutics announced positive full top-line first-in-human results from its Phase 1A clinical trial of ATI-052, a novel anti-TSLP/IL-4Rα bispecific antibody. The trial demonstrated that ATI-052 was well-tolerated with a favorable safety profile, and no impact of anti-drug antibodies on PK or PD was observed. This positive early-stage data is a significant de-risking event for the program, which the company plans to advance into a Phase 2B program for asthma in Q4 2026. Enrollment is also ongoing for Phase 1B trials of ATI-052, with top-line results expected in the second half of 2026. This news provides a strong positive catalyst for the stock, validating its pipeline and potentially attracting further investor interest.
At the time of this announcement, ACRS was trading at $4.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $531.8M. The 52-week trading range was $1.16 to $4.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.